세계의 다한증 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Hyperhidrosis Treatment Market is presumed to reach the market size of nearly USD 1160.21 Million by 2032 from USD 693.17 Million in 2023 with a CAGR of 5.89% under the study period 2024-2032.

Hyperhidrosis treatment involves medical and therapeutic approaches to manage excessive sweating, a condition significantly impacting an individual's quality of life. Hyperhidrosis can affect various body parts, including the palms, soles, underarms, and face, leading to social discomfort and functional impairment. Treatment options range from topical antiperspirants and oral medications to more invasive procedures such as botulinum toxin injections, iontophoresis, and surgical interventions. This treatment aims to reduce excessive sweating, alleviate symptoms, and improve overall well-being. Advances in medical technology and a deeper understanding of the condition have led to the development of more effective and targeted therapies.

MARKET DYNAMICS

The hyperhidrosis treatment market is experiencing significant growth driven by several factors. The rising prevalence of hyperhidrosis, combined with increased awareness and diagnosis of the condition, creates a robust demand for effective treatment options. Advances in treatment technologies, including novel formulations of botulinum toxin and improved iontophoresis devices, offer new solutions for patients seeking more effective management of their symptoms. The rising acceptance of minimally invasive procedures and technological innovations, such as wearable devices for continuous monitoring and targeted treatment, contribute to hyperhidrosis treatment market expansion.

Additionally, the increasing emphasis on quality of life and patient-centric care encourages investment in research and development, leading to new therapeutic options. Expanding telemedicine and remote consultations facilitates treatment access, particularly in underserved regions. Furthermore, collaborations between pharmaceutical companies & research institutions drive innovation and broaden the range of available treatments. However, the high cost of advanced treatments and potential side effects may restrain hyperhidrosis treatment market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Hyperhidrosis Treatment. The growth and trends of Hyperhidrosis Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Hyperhidrosis Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• Axillary
• Palmar
• Plantar
• Other

By Treatment

• Topical
• Oral Medication(Anticholinergics, Other Oral Medications)
• Botulinum Toxin Injections
• Iontophoresis
• Surgical

By Age

• Below 50 Years
• Above 50 Years

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Dermatology Clinics
• Other

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Hyperhidrosis Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Hyperhidrosis Treatment market include AbbVie Inc., Avanor Healthcare Ltd., Brickell Biotech Inc., Dermadry Laboratories Inc., Dermavant Sciences Inc., Hugel Inc., Eirion Therapeutics Inc., Eli Lilly And Company, Intas Pharmaceuticals Ltd., Kaken Pharmaceutical Co. Ltd., Maruho Co. Ltd., MiraDry Inc, SweatBlock. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. HYPERHIDROSIS TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Treatment
  • 3.7.3 Market Attractiveness Analysis By Age
  • 3.7.4 Market Attractiveness Analysis By End-user
  • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. Axillary Historic and Forecast Sales By Regions
• 5.4. Palmar Historic and Forecast Sales By Regions
• 5.5. Plantar Historic and Forecast Sales By Regions
• 5.6. Other Historic and Forecast Sales By Regions

6. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY TREATMENT

• 6.1. Overview By Treatment
• 6.2. Historical and Forecast Data Analysis By Treatment
• 6.3. Topical Historic and Forecast Sales By Regions
• 6.4. Oral Medication(Anticholinergics, Other Oral Medications) Historic and Forecast Sales By Regions
• 6.5. Botulinum Toxin Injections Historic and Forecast Sales By Regions
• 6.6. Iontophoresis Historic and Forecast Sales By Regions
• 6.7. Surgical Historic and Forecast Sales By Regions

7. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY AGE

• 7.1. Overview By Age
• 7.2. Historical and Forecast Data Analysis By Age
• 7.3. Below 50 Years Historic and Forecast Sales By Regions
• 7.4. Above 50 Years Historic and Forecast Sales By Regions

8. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY END-USER

• 8.1. Overview By End-user
• 8.2. Historical and Forecast Data Analysis By End-user
• 8.3. Hospitals Historic and Forecast Sales By Regions
• 8.4. Ambulatory Surgical Centers Historic and Forecast Sales By Regions
• 8.5. Dermatology Clinics Historic and Forecast Sales By Regions
• 8.6. Other Historic and Forecast Sales By Regions

9. GLOBAL HYPERHIDROSIS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE HYPERHIDROSIS TREATMENT COMPANIES

• 10.1. Hyperhidrosis Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF HYPERHIDROSIS TREATMENT INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. AbbVie Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. Avanor Healthcare Ltd.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Brickell Biotech Inc.
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. Dermadry Laboratories Inc.
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Dermavant Sciences Inc.
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. Hugel Inc.
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Eirion Therapeutics Inc.
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Eli Lilly And Company
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Intas Pharmaceuticals Ltd.
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. Kaken Pharmaceutical Co. Ltd.
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments
• 11.13. Maruho Co. Ltd.
  • 11.13.1 Company Overview
  • 11.13.2 Company Revenue
  • 11.13.3 Products
  • 11.13.4 Recent Developments
• 11.14. MiraDry Inc
  • 11.14.1 Company Overview
  • 11.14.2 Company Revenue
  • 11.14.3 Products
  • 11.14.4 Recent Developments
• 11.15. SweatBlock
  • 11.15.1 Company Overview
  • 11.15.2 Company Revenue
  • 11.15.3 Products
  • 11.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies